The study by Bachert et al. found that TRPS1 had expression rates of 31% and 27% in prostate cancer and bladder urothelial carcinoma, respectively, which might be associated with the use of different clones of antibody [28]. This evidence concerns the gene TRPS1 and prostate cancer.